All In Biotech

Drug Trial Radar · NCT06011733

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 133 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

133

Actual

Start

Oct 31, 2023

Primary completion

Feb 5, 2025

Study completion Feb 5, 2025

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Aug 25, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to compare the efficacy of bimekizumab administered subcutaneously (sc) for 16 weeks versus placebo in the treatment of study participants with moderate to severe plaque psoriasis (PSO).

Conditions

  • Chronic Plaque Psoriasis
  • Moderate to Severe Chronic Plaque Psoriasis

Interventions

  • PlaceboOther

    Study participants will receive placebo subcutaneously at pre-specified time points in the placebo arm as comparator and in the bimekizumab arm to maintain the blinding.

  • BimekizumabDrug

    Study participants will receive bimekizumab (dosage regimen 1 and 2) subcutaneously administered at pre-specified time points during the Initial and Maintenance Treatment Periods.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Psoriasis Area Severity Index 90 (PASI90) Response at Week 16Time frame: Week 16
  2. Percentage of Participants With Investigator´s Global Assessment (IGA) 0/1 Response at Week 16Time frame: Week 16

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Ps0041 20023

    Beijing, China

  • Ps0041 20247

    Beijing, China

  • Ps0041 20306

    Beijing, China

  • Ps0041 20117

    Guangzhou, China

  • Ps0041 20311

    Guangzhou, China

  • Ps0041 20313

    Guangzhou, China

  • Ps0041 20022

    Hangzhou, China

  • Ps0041 20193

    Hangzhou, China

  • Ps0041 20296

    Hangzhou, China

  • Ps0041 20312

    Jinan, China

  • Ps0041 20318

    Jinan, China

  • Ps0041 20310

    Ningbo, China

  • Ps0041 20308

    Shanghai, China

  • Ps0041 20184

    Shenzhen, China

  • Ps0041 20136

    Tianjin, China

  • Ps0041 20120

    Wuhan, China

  • Ps0041 20314

    Wuxi, China

  • Ps0041 20309

    Xi'an, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.